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Abstract
Background: Testing strategies is crucial for genetics clinics and testing laboratories. In this study, we tried to
compare the hit rate between solo and trio and trio plus testing and between trio and sibship testing. Finally, we
studied the impact of extended family analysis, mainly in complex and unsolved cases.
Methods: Three cohorts were used for this analysis: one cohort to assess the hit rate between solo, trio and trio
plus testing, another cohort to examine the impact of the testing strategy of sibship genome vs trio-based analysis,
and a third cohort to test the impact of an extended family analysis of up to eight family members to lower the
number of candidate variants.
Results: The hit rates in solo, trio and trio plus testing were 39, 40, and 41%, respectively. The total number of
candidate variants in the sibship testing strategy was 117 variants compared to 59 variants in the trio-based
analysis. We noticed that the average number of coding candidate variants in trio-based analysis was 1192 variants
and 26,454 noncoding variants, and this number was lowered by 50–75% after adding additional family members,
with up to two coding and 66 noncoding homozygous variants only, in families with eight family members.
Conclusion: There was no difference in the hit rate between solo and extended family members. Trio-based
analysis was a better approach than sibship testing, even in a consanguineous population. Finally, each additional
family member helped to narrow down the number of variants by 50–75%. Our findings could help clinicians,
researchers and testing laboratories select the most cost-effective and appropriate sequencing approach for their
patients. Furthermore, using extended family analysis is a very useful tool for complex cases with novel genes.
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Background
The advent of next-generation sequencing applications
and technologies has provided a low-cost opportunity to
examine a patient’s genome and establish molecular
defects [1–3]. The clinical evaluation of patients with
genetic disorders currently involves whole-exome se-
quencing (WES) or whole-genome sequencing (WGS),
and the diagnostic yield generally ranges between 25 and
49% in some populations, with a maximum yield of 40–
44% in trio analysis [4, 5]. The diagnostic yield of WGS
ranges between 7 and 20% [6]. Furthermore, family-
based analysis and studies of next-generation sequencing
provide considerable power to detect common and rare
variants [7], and family-based designs can be helpful for
cosegregation (e.g., for prioritizing variants and genes)
[8]. Additionally, several genes and disorders have been
discovered by testing extended consanguineous families
[9–11], mainly by autozygome and exome analysis [12].
However, one of the major limitations of these technolo-
gies in addition to their cost is the data interpretation.
On average, WES costs approximately $1500, and WGS
costs approximately $4000; the average number of called
variants in the variant call format (VCF) file in WES is
approximately 70,000 compared with approximately 5,
000,000 in WGS. Therefore, finding the right approach
for each case is crucial for clinicians to reach a final
diagnosis as well as for the health system to direct its
budget by providing the right test. In this study, we ex-
amined the best testing strategy by comparing the hit
rate of solo cases compared with the rate obtained by
extending the test to other family members (trio or trio
plus). Furthermore, we analyzed the impact of family
structure in cases of trio-based analysis compared with
sibship testing. Moreover, we studied the impact of test-
ing extended family members (up to eight members) on
narrowing the possible candidate variants, which would
require further investigation and manual curation.
Methods
We retrospectively reviewed all genetic cases that has
been seen at the genetic clinic at King Abdulaziz Med-
ical City, Riyadh, Saudi Arabia. Only patients who
underwent DNA sequencing; either WES or WGS were
recruited for the study. Data collection from patient’s
electronic medical records, as well as further analysis
were done for eligible patients. Clinical next-generation
sequencing based tests (WES and/or WGS) were per-
formed in commercial CAP/CLIA-accredited laborator-
ies. For the extended family analysis, WGS was carried
out either in clinical CAP/CLIA-accredited laboratories
or in a research laboratory at King Abdullah University
of Science and Technology (KAUST) as part of a collab-
orative project. Illumina NextSeq, Illumina HiSeq or Ion
Proton sequencers were used for WES. For WGS, only
HiSeq 4000 sequencer were used. Cases who have been
tested with WES requires ~90x depth of coverage, and
the minimum coverage for any variant to be considered
is 20x. The average coverage depth for WGS cases was
~30X. The configuration of the pipeline was based on
the sequencing systems and types of kit. Ethical approval
for this study was obtained from the Institutional Re-
search Board of the King Abdullah International Medical
Research Center (KAIMRC) with a reference study num-
ber RC 16/113 and RC16/211/R2.
In order to obtain a diagnosis for cases that has been
sent for genetic testing, several factors incorporated in to
reach one (or few) pathogenic variants. These factors in-
clude but not limited to: 1) the patient clinical presenta-
tion, 2) mode of inheritance observed in the family, 3)
results of additional metabolic analysis, 3) allele frequency
in population databases, and others. When considering
testing the extended family to facilitate the analysis; the
testing cost and hit rate are the major two considerations.
For the different analyses, we divided our main cohort
into three cohorts. The first was a clinical cohort used to
assess the hit rate of each test type (solo vs. trio vs. trio
plus). The second cohort was used to assess the testing
strategy between trio-based analysis and siblings only
with no parents for the trio vs. sibship-based analysis.
The third cohort was employed to assess the impact of
testing additional family numbers on the total number
of candidate variants for the extended family analysis.
Each cohort structure is illustrated in Fig. 1.
Cohort structures
Clinical cohort
In this cohort, families were tested for complete clinical
analysis, including variant confirmation and clinical
reporting. All clinical cases that underwent WES and/or
WGS between 2014 and 2018 were enrolled irrespective
of their phenotype. Cases were sorted based on their test
type (solo, trio or trio plus), where solo indicates testing
performed only in the index case; trio indicates testing
performed on the index case and both parents; and trio
plus indicates testing performed on the index case, both
parents and an additional sibling (either affected or not af-
fected). Finally, we classified each identified variant for
clinical significance as pathogenic/likely pathogenic (P/
LP), a variant of uncertain significance (VUS) or benign
according to the ACMG criteria [13]. Detailed clinical in-
formation in the human phenotype ontology (HPO) for-
mat and the variant classification of all positive and
inconclusive cases are provided in supplementary material
Variant Database (Additional file 3). All identified disease-
causing variants in this cohort were confirmed by either
Sanger sequencing or fragment analysis. Several tools were
used for the raw data analysis, including Alamut® Visual
(http://www.interactive-biosoftware.com/alamut-visual/),
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BaseSpace Variant Interpreter (https://variantinterpreter.
informatics.illumina.com/), Ingenuity Variant Analysis -
QIAGEN Bioinformatics (https://variants.ingenuity.com/
va/), Varsome The Human Genomics Community
(https://varsome.com/), the UCSC Genome Browser
(https://www.genome.ucsc.edu/) and the Integrative Gen-
omics Viewer [3].
Trio vs. sibship testing
In this cohort, we enrolled families with a family history
suggestive of autosomal recessive disorders and five
members (index, both parents and two siblings) for the
raw data analysis. Then, we compared the number of
coding variants in the same family in the trio-based ana-
lysis (index and parents), where the variant was present
in both parents in a heterozygous state and in a homozy-
gous state in the index patient, with the sibship-based
analysis (index and siblings with no parents), based on
health status and the shared and nonshared variants be-
tween affected and nonaffected siblings.
Extended family analysis cohort
This cohort mixed families from the clinical and other re-
search cohorts to analyze the number of candidate vari-
ants based on the family structure using family-based
designs (e.g., co-segregation for prioritizing variants and
genes). For the extended family analysis, we only used the
vcf files generated by the local pipeline. We considered
families in which three or more individuals were being
tested in this analysis. Candidate variants were considered
after annotating the variants as either coding or noncod-
ing (exonic or intronic) variants based on the most severe
impact at the mRNA and transcript levels. The total num-
ber of identified variants was based on the index case and
then narrowed by adding family members (supplementary
material Table 2). The extended family analysis focused
on the shared and nonshared variants between affected
and nonaffected individuals; both homozygous and het-
erozygous variants were considered.
Results
Clinical cohort
The cohort comprised 1091 individuals from 435 families.
In 322 families (74%), the index was in the pediatric age
group (< 12 years), and in 113 (26%), the index belonged
to the adult group; 237 (54%) were male, and 196 (45%)
were female. All cases were enrolled through the genetics
clinic and received a complete clinical evaluation, includ-
ing metabolic workup, array comparative genomic
hybridization, WES and then WGS if all the previous ana-
lyses were negative. In total, 74% were consanguineous
families compared with 24% nonconsanguineous, and 2%
had an unknown status. The overall hit rate of all the co-
horts (WES +WGS) was 40% (WES = 47%, WGS = 15%).
The complete breakdown of the results is provided in the
supplementary material (Table 1).
Fig. 1 illustration of the three cohort structures enrolled in this study. a Clinical testing cohort with the number of enrolled families, individuals
and test type; the white rectangle represents the positive results for each test type. b Trio vs. sibship cohort, with the number of candidate
variants. c Extended family analysis cohort; the white rectangle shows the number of candidate variants after adding each family member.
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Hit rate in solo, trio and trio plus
The total number of WES cases was 335 (110 solo, 172
Trio, 53 Trio plus), of the solo cases, 52 (47%) were posi-
tive, compared with 79 (46%) of trio and 27 (51%) of trio
plus cases were positive. The total number of WGS cases
was 100 (35 solo, 42 Trio, 23 Trio plus), of the solo cases
5 (14%) were positive, compared with 6 (14%) of trio cases,
and 4 (17%) of trio plus cases were positive (Fig. 2).
Trio plus affected and trio plus nonaffected
In total, 76 families underwent trio plus testing, 53 fam-
ilies underwent WES, and 23 families underwent WGS.
The WES cases were divided into 41 families with af-
fected individuals and 12 families with unaffected indi-
viduals. The hit rate between the two cohorts was 51%
(21/41 families) when the trio plus family member was
affected and 50% (6/12 families) when the trio plus fam-
ily member was nonaffected. For the WGS cases (23
families), 15 families had affected individuals, and eight
families had unaffected individuals. The hit rate was 13%
among the affected plus cohort (2/15 families) and 25%
in the nonaffected plus cohort (2/8 families) (supple-
mentary material Table 1).
Mode of inheritance and testing type
If we consider the mode of inheritance as a clinical guide
to testing, among all the positive cases with a family his-
tory suggestive of autosomal recessive disorders, the
positive results were 70% in solo testing (40 cases), 75%
in trio testing (64 cases) and 71% in trio plus testing (22
cases). For families with a suggestive autosomal domin-
ant mode of inheritance, the positive results for solo, trio
Table 1 Showing the number of test type (enrolled family
members for testing), and the total number of families for each
test type for example we have 8 families where we tested 4
individuals (trio plus), 6 individuals underwent WES, and 2
individuals underwent WGS
Test type Total number of families WES WGS
3 (Trio) 20 13 7
4 (Quartet) 8 6 2
5 (Quintet) 10 5 5
6 (Sextet) 4 0 4
7 (Septet) 2 0 2
8 (Octet) 3 0 3
Fig. 2 Breakdown of the hit rate by test type. A) for WES and B) for WGS
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and trio plus were 25% (14 cases), 20% (17 cases), and
13% (4 cases), respectively (supplementary material file 1:
Table 1).
Sibship testing cohort
For the trio vs. sibship genome, we enrolled families to
test the best strategy and compared the trio-based ana-
lysis with testing siblings. In particular, we compared
trio-based testing where the index and both parents
were involved in sibship genome testing without parents.
This approach examined the number of candidate vari-
ants in the trio-based analysis vs. testing siblings without
parents in families with a family history highly suggestive
of autosomal recessive disorders to lower the number of
candidate variants. For this analysis, we had 15 families
with five members, and raw data, detailed family pedi-
grees (Additional file 2) are provided in the supplemen-
tary material. We compared the number of coding
variants in the trio-based analysis, where the variant was
present in both parents in the heterozygous state and in
the index patient in the homozygous state, with testing
only siblings without parents. We found that the average
number of candidate variants in the trio-based analysis
was 59 compared with 117 under the sibship testing
strategy (Fig. 1). When we consider if all the siblings are
affected (nonaffected), the average number of shared
homozygous variants is 90 (88) variants. However, these
are the raw results and had limited statistical significance
due to the sample size limitation, which occurred be-
cause of the testing costs.
Extended family analysis cohort
This cohort includes 47 families (204 individuals) (Table
1). For the extended family analysis; we used the VCF
files from families to test the impact of testing additional
family members to lower the number of candidate vari-
ants that would require further analysis. In particular,
we assessed shared and nonshared variants among af-
fected and nonaffected family members based on differ-
ent modes of inheritance and allele state. After applying
basic filters, including quality filters and allele fre-
quency < 1.5%, we found 27,646 variants in trio families.
We split the analysis into two types: (i) coding and non-
coding variants and (ii) homozygous and heterozygous
variants. Here, variants on the X chromosome were con-
sidered homozygous in cases of males. After we applied
filters to look for shared variants between affected mem-
bers, the number of candidate variants dropped by 50–
75% after using the parent results (trio-based analysis)
and by 25–50% after adding each additional family
member. The average coding homozygous candidate
variants dropped to only <= 6 variants after adding the
fifth family member and to 2 coding variants after add-
ing the eighth family member. The coding heterozygous
variants dropped to 100 variants after adding the sixth
family member and to 43 in families with eight family
members. The average number of noncoding variants
per index was 72,660 after passing the threshold for
quality and allele frequency. However, after adding the
eighth family member, the number of noncoding vari-
ants dropped to 66 homozygous and 135 heterozygous
variants (Table 2, Fig. 3).
Discussion
In this study, we examined the advantages of additional
family members. Previously, we noticed no differences in
the hit rate between solo and trio in our population, and
we wanted to further test this observation [3, 4]. In this
analysis, we confirmed that the hit rate between solo and
other extended family analyses has limited clinical utility.
One possible explanation is that the majority of the disease-
causing variants in our population were homozygous in the
autosomal recessive disorder where both parents were car-
riers. Furthermore, autosomal dominant disorders account
for only 10% of all detected disorders in genetics clinics
[4, 5], and our cohort of both adult and pediatric cases
would capture autosomal dominant late-onset disor-
ders. However, even with similar hit rates, one of the
advantages of trio or trio plus testing over solo testing
is reducing the turnaround time and providing results
Table 2 Showing the average number of variants either shared
or not shared after adding each family member (complete
details about filtration process of shared not shared variants are
provided in supplementary material file 1:Table 2)
Coding
Number of tested
individuals
Total
Variants
Homozygous
Variants
Heterozygous
Variants
Index 1196 165 1031
Trio 1010 38 972
Quartet 591 20 571
Quintet 242 6 236
Sextet 104 4 100
Septet 84 3 81
Octet 45 2 43
Non-Coding
Number of tested
individuals
Total
Variants
Homozygous
Variants
Heterozygous
Variants
Index 72,660 9162 63,498
Trio 15,451 1361 14,090
Quartet 11,410 660 10,750
Quintet 6309 174 6135
Sextet 3757 113 3644
Septet 2792 111 2681
Octet 201 66 135
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faster than by performing segregation analysis for the
candidate variants.
After considering family history as a clinical tool to de-
termine the testing type, we found no differences in the
hit rate (solo vs. trio vs. trio plus) between families with
autosomal recessive disorders and families with auto-
somal dominant disorders. This extended testing showed
no additional advantages for the hit rate, but it might
provide useful information for databasing.
In large families, it is always challenging for clinical ge-
neticists and genetics counselors to decide who to test. To
further evaluate the impact of additional family members,
we tested the power of lowering the possible candidate
variants that would require further evaluation. For homo-
zygous variants that support autosomal recessive disor-
ders, testing parents under the traditional trio-based
approach would provide a lower number of candidate var-
iants compared with sibship testing with no parents.
To test the impact of adding family members to the
number of candidate variants, we found that each add-
itional family member could lower the number of
candidate variants in the coding region by 25–50%.
Hence, while this method might be expensive, we could
solve two cases and establish the molecular defect
(underwork in different research project). However, this
approach might not always explain the phenotype if the
variants are in genes unrelated to the phenotype or if
the variants are in novel genes, and further research is
required to investigate the gene function and relation
with the phenotype.
In addition, we previously showed the limited clinical
utility of WGS compared with WES [5]. In this study,
we confirmed our previous observations. Indeed, of all
14 of the cases identified by WGS, the variant was called
in the vcf files from the exome in 13 cases. One possible
explanation for overlooking these cases during the ana-
lysis rather than the advantages of WGS is that we tend
to consider WGS as a more rigorous form of testing.
Moreover, we examine the VCF file in more detail than
with WES data, which normally passes through the rou-
tine pipeline of clinical evaluation. We re-emphasize our
previous recommendation to reanalyze WES before
Fig. 3 a Average number of coding variants for the extended family analysis. b Average number of non-coding variants for the extended
family analysis
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performing WGS. This would improve the hit rate of
WES and save a significant amount of money. For ex-
ample, in one case, we performed WGS trio plus, which
cost approximately $13,000, and we identified a missense
variant that was found by WES but overlooked during
the analysis; in another example, we spent approximately
$100,000 on only three families to perform WGS for all
eight family members. This amount could be saved, and
we could test sixty-six families for solo WES and reach a
similar diagnostic hit rate. Furthermore, the average
number of total called variants in WGS is 5,000,000 per
individual, and even with trio or trio plus family analysis,
the average number of identified variants would drop to
8000–15,000 after applying all routine filters (allele fre-
quency, low quality, shared and nonshared variants),
with approximately 96–97% being intronic variants.
With the current stage of knowledge, it is not possible
to examine this large number of variants, and testing la-
boratories focus only on 2–3%, which covers the coding
exonic part of the genome, or look for previously re-
ported intronic variants. Therefore, until the price of ge-
nomes falls or knowledge and databases grow to
increase our understanding of the noncoding regions for
analysis and classification, we recommend performing
WES and a reanalysis of the raw data from WES.
While solo exome testing might provide the best clin-
ical practice in our population, there might be other sce-
narios in which extended analysis is required, such as
when results are urgently required for medical or non-
medical reasons, when other family members might not
be available in future visits or when segregation analysis
for any identified variant is not possible.
Conclusion
There was no difference in the hit rate between solo and
extended family members. Trio-based analysis was a bet-
ter approach than sibship testing. However, each add-
itional family member helped to narrow down the
number of variants by 50–75%. These findings could help
clinicians, researchers and testing laboratories select the
most cost-effective and appropriate sequencing approach
for their patients. As with any research, some potential
limitations should be further studied in future researches.
For instance, this study needs to be extend to wider range
of individuals as our study is limited by a small sample size
due to the nature and cost of WES and WGS.
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